<DOC>
	<DOCNO>NCT00992784</DOCNO>
	<brief_summary>The purpose study evaluate safety GSK Biologicals ' influenza vaccine . Elderly subject randomize primary study ( NCT00760617 ) receive vaccine third time . For study mask `` observer-blind '' elderly subject `` open '' young adult subject .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity GlaxoSmithKline Biologicals ' Influenza Vaccine Elderly People</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects investigator believe comply requirement protocol enrol study . Specific attention give compliance potential subject suspect drug alcohol abuse . A male female age 1943 year &gt; =66 year time vaccination participate study NCT00760617 complete 6month followup . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation enter study . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception 2 month vaccination . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Use investigational nonregistered product study vaccine ( ) within 30 day prior vaccination , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration influenza vaccine study vaccine vaccine foreseen study protocol entire study period . Vaccination influenza since January 2009 seasonal influenza vaccine . Chronic administration immunosuppressant immunemodifying drug within six month prior administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History hypersensivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine ( ) . Acute clinically significant pulmonary , cardiovascular , hepatic , renal , neurological psychiatric disorder , determine clinical evaluation preexist laboratory screening test . Acute disease and/or fever time enrolment . Fever define temperature &gt; =37.5Â°C oral setting . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan administration study . Any medical condition IM injection contraindicate Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza Vaccines</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2186877A</keyword>
	<keyword>influenza infection</keyword>
</DOC>